⚠ Unsupported Browser ⚠
Our site probably won't work so great in Internet Explorer. Please try a more recent version of a major browser
like Chrome, Firefox, Safari, or Edge.
Hybrid Closed Loop (insulin pump) trial
In people with Type 1 diabetes tight glucose control protects against diabetes complications and improves some aspects of quality of life. Hybrid Closed Loop (HCL) systems include an insulin pump and a continuous glucose monitor that measures glucose levels in the tissue under the skin and controls the rate of insulin delivery. Led by Prof. David O’Neal in 7 Australian sites in 140 adults with Type 1 diabetes the effects of 6-months HCL pump use (compared to multiple daily insulin injections) is being studied. Study outcomes relate to various aspects of glucose control, sleep quality, mental well-being, risk factors for vascular disease and driving safety. Results are being analysed and will be reported in 2020. A similar multi-site study, led by Prof. Tim Jones is being conducted in 120 children with Type 1 diabetes will complete in 2020.
Relevant Publications
HbA1c variability in adults with type 1 diabetes on continuous subcutaneous insulin infusion (CSII) therapy compared to multiple daily injection (MDI) treatment.
2019 BMJ Open
10.1136/bmjopen-2019-033059
Glucose and Counterregulatory Responses to Exercise in Adults With Type 1 Diabetes and Impaired Awareness of Hypoglycemia Using Closed-Loop Insulin Delivery: A Randomized Crossover Study.
2020 Diabetes Care
10.2337/dc19-1433
Glucose Control Using a Standard Versus an Enhanced Hybrid Closed Loop System: A Randomized Crossover Study.
2019 Diabetes Technology & Therapeutics
10.1089/dia.2018.0279
Effect of 6 months hybrid closed-loop insulin delivery in young people with type 1 diabetes: a randomised controlled trial protocol.
2018 BMJ Open
10.1136/bmjopen-2017-020275
Closed-Loop Insulin Delivery for Adults with Type 1 Diabetes Undertaking High-Intensity Interval Exercise Versus Moderate-Intensity Exercise: A Randomized, Crossover Study.
2017 Diabetes Technology & Therapeutics
10.1089/dia.2016.0461
“It Is Definitely a Game Changer”: A Qualitative Study of Experiences with In-home Overnight Closed-Loop Technology Among Adults with Type 1 Diabetes.
2017 Diabetes Technology & Therapeutics
10.1089/dia.2017.0007
Overnight Counter-Regulatory Hormone Levels and Next Day Glycemia in Adults with Type 1 Diabetes During Closed-Loop Insulin Delivery Versus Sensor-Augmented Pump with Low-Glucose Suspend.
2017 Diabetes Technology & Therapeutics
10.1089/dia.2017.0049
Glycemia, Treatment Satisfaction, Cognition, and Sleep Quality in Adults and Adolescents with Type 1 Diabetes When Using a Closed-Loop System Overnight Versus Sensor-Augmented Pump with Low-Glucose Suspend Function: A Randomized Crossover Study.
2016 Diabetes Technology & Therapeutics
10.1089/dia.2016.0288
